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Antiplatelet agents (APA) are used to reduce the risk of major cardiovascular events in various settings. When used for
secondary prevention, antiplatelet monotherapy is associated with a relative risk reduction of such ischemic events of 25%
compared to a placebo. New strategies are based on dual APA therapy. Aspirin-clopidogrel combination therapy is effective
in situations of acute vessel injury such as myocardial infarction, coronary stenting and, possibly, peripheral stenting.
GPIIb/IIIa inhibitors and loading doses of clopidogrel also have a place in these acute settings. In contrast, the aspirin-
clopidogrel combination has proven disappointing in stable patients with cardiovascular disease, with no beneficial effect
and, often, more bleeding events. Combination therapy with aspirin and extended-release dipyridamole may be more beneficial
than very low doses of aspirin in ischemic stroke, but its use is limited by adverse effects. Overall, aspirin remains the first-line
monotherapy of choice for patients with atherothrombosis, while clopidogrel is a valuable alternative. New antiplatelet
strategies are in the pipeline, and clinically relevant laboratory tests of APA response may soon help to tailor treatment.
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Platelets contribute to the initiation and aggravation
of atherosclerosis in humans and in animal models.
Major steps in arterial thrombosis include platelet
activation and aggregation, both following contact
with subendothelial structures and via thrombin gen-
eration.1 Antiplatelet agents (APA) are therefore key
tools in the treatment of atherothrombosis. In addition
to their well-established role in thrombus formation,
there is growing evidence that platelets are also
involved in the progression of atherosclerotic lesions.
When activated, platelets release granules containing
cytokines and growth factors that, together with
thrombin, contribute to themigration and proliferation
of smooth-muscle cells and monocytes.2 Thus, in
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APA can also inhibit the platelet contribution to lesion
progression.3,4
There are currently four major classes of antiplate-
let drugs. Aspirin, thienopyridines (ticlopidine and
clopidogrel) and phosphodiesterase (PDE) inhibitors
(dipyridamole and cilostazol) are platelet function
inhibitors, while the glycoprotein (GP) IIb/IIIa antag-
onists specifically prevents aggregation by inhibiting
the fibrinogen receptor aIIbb3.
For several years a one-drug-fits-all policy gov-
erned the secondary prevention of ischemic events
in cardiovascular patients. Aspirin was most often
prescribed. Recently, several trials have tested the
efficacy and safety of new APA strategies, mostly
APA combinations, in secondary prevention – the
subject of this review.
Role of Platelets in Atherothrombosis
Platelet activation involves several mechanisms. After
atherosclerotic plaque rupture, platelet adherence to
subendothelial components like collagen triggers
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formation of a stable thrombus. Soluble agonists like
thromboxane A2 (TA2) and adenosine diphosphate
(ADP) are the main amplifiers of platelet activation
(Fig. 1). Following platelet activation the GPIIb/IIIa
receptor undergoes a conformational change that al-
lows activated platelets to stick together via bridges
formed by the GPIIb/IIIa complex and proteins such
as fibrinogen, fibrin, and von Willebrand factor. Acti-
vated platelets also stimulate the coagulation cascade
and accelerate thrombin formation, further contribut-
ing to thrombus growth.
Aspirin
The antiplatelet effect of aspirin is mainly due to irre-
versible inhibition of cyclooxygenase (COX)-1 activity,
which normally catalyzes the conversion of arachi-
donic acid to prostaglandin (PG) H2. PGH2 is a pre-
cursor of several bioactive prostanoids, including
TA2.5 Although aspirin has a short half-life (15 to
20 min) in the human circulation, it induces a rapid
and permanent defect in TA2-dependent platelet
function. As only 10% of the platelet pool is replen-
ished each day, a single daily dose of aspirin is suffi-
cient to maintain virtually complete inhibition of
platelet TA2 production.6
The ISIS-2 study represented an important
milestone, by showing that aspirin reduced mortality
after a myocardial infarction (MI) as effectively as
streptokinase.7 Several other trials followed, anda meta-analysis showed a 25% relative reduction in
the risk of vascular death, myocardial infarction
and stroke with antiplatelet therapy (mostly aspirin)
compared to a placebo in various categories of high-
risk cardiovascular patients.8 In patients with acute
myocardial infarction, the absolute reduction in risk
was 3.8% at 1 month and the ‘‘number needed to treat’’
(NNT) for onemonth to avoid onemajor vascular event
was 26. Current evidence suggests that a daily aspirin
dose of 75e160 mg is optimal for long-term prevention
in high-risk patients, together with a loading dose of
325 mg when an immediate antithrombotic effect is
required (Table 1).9,10
The benefit of aspirin on coronary heart disease
and stroke has been extensively studied, whereas
fewer data are available on peripheral arterial disease
(PAD). PAD is often associated with atherosclerosis in
other vascular territories, and patients with this dis-
order are at markedly elevated risk of vascular events
and death.11 However, among 9214 patients with PAD
included in the Antithrombotic Trialists’ Collabora-
tion Study, the 22% reduction in ischemic events
referred to other APA than aspirin in 60% of cases.
Nevertheless, the benefit of aspirin on cardiovascular
events has been firmly demonstrated in a number of
other high-risk settings,12 and PAD patients are
clearly a high-risk population.13
Aspirin is the antiplatelet drug recommended for
PAD in theAmerican College of Cardiology/American
Heart Association guidelines14 (level of evidence: A).
The Inter-Society Consensus for the Management ofcAMP
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Fig. 1. Main amplification pathways of platelet activation and action of antiplatelet agents (APA). The two main amplifica-
tion pathways are the thromboxane A2 (TA2) and adenosine diphosphate (ADP) pathways, which are targeted by the
most widely used APAs. AA: arachidonic acid, cAMP: cyclic adenosine monophosphate, PDE: phosphodiesterases.Eur J Vasc Endovasc Surg Vol 34, July 2007
12 P. Fontana and J.-L. RenyPeripheral Arterial Disease (TASC II)15 is more circum-
spect, with a grade-C level of evidence, probably
because of the lack of powered placebo-controlled
trials in this setting,16 which is unlikely to be run owing
to ethical issues.
The Drug Evaluation in Atherosclerotic Vascular
Disease in Diabetes (DAVID) study17 showed a 45%
reduction in all-cause mortality among patients with
PAD and diabetes treated with picotamide (a com-
bined inhibitor of TA2 synthase and receptor) com-
pared with aspirin. However, these promising data
need to be confirmed in a larger population before
picotamide can be considered as a replacement for
aspirin in patients with PAD.
Thienopyridines
Thienopyridines are prodrugs that need to be acti-
vated by liver cytochrome P450 isoenzymes and can
therefore only be taken orally.18 The active metabolite
selectively targets P2Y12,19 one of the two ADP recep-
tors on the platelet surface, and irreversibly binds two
Table 1. Antiplatelet treatments and their indications.9,10,14,15,54e58
Recent studies have not added significant modifications
Clinical condition Current indications
from consensus
statements
Ischemic heart disease
Acute coronary artery injury (MI, stenting)
Dual aspirin-clopidogrel treatment Yes e 1 to 12 months
Clopidogrel loading dose Yes e 300 to 600 mg
GPIIb IIIa inhibitors Yes
Stable IHD
Aspirin Yes e 75 to 325 mg/d
Clopidogrel Yes e 75 mg/d
Dual aspirin-clopidogrel treatment No
Ischemic cerebral disease
Acute stroke
Aspirin Yes 160e300 mg
Clopidogrel No
Dual aspirin-clopidogrel treatment No
Dual aspirin-dipyridamole treatment No
Stable disease
Aspirin Yes e 75 to 325 mg/d
Clopidogrel Yes e 75 mg/d
Dual aspirin-clopidogrel treatment No
Dual aspirin-dipyridamole treatment Yes
Peripheral arterial disease
Acute vessel injury (stenting)
Dual aspirin-clopidogrel treatment Yes
Stable PAD
Aspirin Yes e 75 to 325 mg/d
Clopidogrel Yes e 75 mg/d
Dual aspirin-clopidogrel treatment NoEur J Vasc Endovasc Surg Vol 34, July 2007cysteine residues. The thienopyridines induce perma-
nent platelet hypo-responsiveness to ADP.
Ticlopidine was the first thienopyridine to arrive on
the market, but the risk of neutropenia (in about 1% of
patients) and thrombotic thrombocytopenic purpura
(0.02%) limited its use. Clopidogrel, with lower side
effects, has now largely supplanted ticlopidine.
As thienopyridines have to be metabolized before
becoming active, there is a time lag before their anti-
platelet action occurs. Inhibition of ADP-induced
platelet aggregation reaches its plateau after 5 days
of standard-dose therapy (500 mg/d ticlopidine or
75 mg/d clopidogrel).20 After acute vessel injury,
such as following coronary stenting, the onset of clo-
pidogrel action can be brought forward to between
2 and 5 hours by giving a loading dose.21 Two pro-
spective studies showed that a 600-mg loading dose
of clopidogrel before PCI for elective indications or
for non ST-elevation myocardial infarction was safe
and more effective than the standard 300-mg dose
on recurrent ischemic events.22,23 Finally, the ALBION
study (Assessment of the Best Loading Dose of Clopi-
dogrel to Blunt Platelet Activation, Inflammation and
Ongoing Necrosis) suggested an incremental benefit
of a 900-mg loading dose.24
The CAPRIE study evaluated the efficacy and
safety of clopidogrel compared to aspirin for second-
ary prevention in 19185 cardiovascular patients.25 It
showed a relative reduction in the risk of myocardial
infarction, ischemic stroke and vascular death of 8.7%
( p¼ 0.04), after a mean follow-up of 1.9 years, and an
absolute risk reduction of 0.51% per year (NNT¼ 196
to avoid one ischemic event). Subgroup analyses
suggested that the clinical benefit was greater in
PAD patients25 and other high-risk patients.26 How-
ever, it should be noted that many hypotheses raised
by subgroup analyses were subsequently refuted
in trials specifically designed to test them,27 and
that prospective studies are still needed to identify
patients with stable vascular disease who might ben-
efit more from clopidogrel than from aspirin.
Thienopyridines and aspirin act on the two main
physiological platelet amplification pathways (the
ADP and TA2 pathways, respectively), therefore
their combination might be beneficial for patients
with a high risk of vascular occlusion. This issue
was evaluated in acute coronary injury and stable
cardiovascular diseases.
Dual clopidogrel and aspirin therapy in acute
coronary injury
The CURE study (Clopidogrel in Unstable angina to
prevent Recurrent Events) showed that clopidogrel,
13New Antiplatelet Strategies in Atherothrombosis and Their Indicationsgiven topatientswithunstable anginaor acuteMIwith-
out ST elevation, yielded a 2.1% absolute reduction
(NNT¼ 48, p< 0.0001) in the risk of major ischemic
events.28 Recent studies include the CLARITY-
TIMI 28 trial (Clopidogrel as Adjunctive Reperfusion
Therapy e Thrombolysis In Myocardial Infarction)
which demonstrated the benefit of clopidogrel, given
in addition to fibrinolytic therapy and aspirin, in
patients presenting within 12 hours after the onset
of MI with ST elevation.29 Clopidogrel addition to
the standard therapy yielded a relative reduction of
37% (95% CI [24e47], p< 0.001) and an absolute
reduction of 6.7% (NNT¼ 15) in the frequency of
a composite endpoint (occluded infarct-related artery
on angiography, or death or recurrent myocardial
infarction before angiography). This effect was main-
tained at 1 month, with an absolute reduction of 2.5%
( p¼ 0.03) in a composite clinical endpoint consisting
of major ischemic events. These results are in line
with those of the ClOpidogrel and Metoprolol in Myo-
cardial Infarction Trial (COMMIT),30 in which 45852
patients admitted for suspected acute MI were ran-
domly allocated either to clopidogrel 75 mg daily
(n¼ 22 961), without a loading dose, or to a matching
placebo (n¼ 22 891), in addition to aspirin 162 mgdaily.
Allocation to clopidogrel was associated with an abso-
lute reduction of 0.9% (NNT¼ 111, p¼ 0.002) in the risk
of death, reinfarction or stroke.
Aspirin-thienopyridine combination therapy is now
the standard preventive treatment after percutaneous
coronary intervention (PCI) with stent implantation,
as it is superior to anticoagulation31,32 and to aspirin
alone.33,34 The recommended duration of aspirin-
clopidogrel combination therapy after acute coronary
artery injury ranges from 1 to 12 months (Table 1)
and is controversial, particularly in view of late
thrombosis after APA withdrawal in patients with
drug-eluting stents (DES).35 By analogy with PCI,
thienopyridines and aspirin are also combined after
stent implantation in the renal and lower-limb ar-
teries, even though there are no consistent data
supporting this strategy. The results of ongoing trials
in this indication are eagerly awaited, including
those of the CAMPER study (Effect of Clopidogrel
vs. Placebo, on a Background of Standard Care
including Aspirin, in Maintaining the Patency of
Lower Limb Arteries After Angioplasty).
Dual clopidogrel and aspirin therapy in stable
cardiovascular diseases
Contrary to situations of acute coronary artery injury,
aspirin-thienopyridine combination therapy has been
so far disappointing in other clinical settings.In ischemic cerebrovascular disease (ICD), The
MATCH trial (Management of Atherothrombosis
With Clopidogrel in High-Risk Patients) randomised
7599 patients with a recent transient ischemic attack
(TIA) or ischemic stroke to either clopidogrel plus as-
pirin (both 75 mg daily) or clopidogrel plus placebo
during 18 months.36 The dual APA strategy did not
show any supplementary reduction in the composite
endpoint of ischemic stroke, myocardial infarction,
vascular death, or readmission for acute ischemia,
and was associated with an increase in hemorrhagic
complications (1.9%, vs 0.6% P< 0.001). The design
of the study also raised several concerns, including
the absence of an aspirin arm, despite the lack of
proven efficacy of clopidogrel compared to aspirin
in these acute (<7 days) neurovascular patients.37
The high percentage (53%) of infarcts related to
small-vessel disease is a matter of concern, as the
pathophysiology of arterial occlusion may be different
in small-vessel disease compared to typical athero-
thrombotic vascular lesions.38
The CHARISMA study (Clopidogrel for High
Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance) was designed to test
the hypothesis that ‘‘long-term treatment with a com-
bination of clopidogrel plus aspirin might provide
greater protection against cardiovascular events than
aspirin alone in a broad population of patients at
high risk’’.39 This trial enrolled over 15000 patients,
who were randomized and followed for a median of
28 months. The primary combined endpoint myocar-
dial infarction, stroke, and death from cardiovascular
causes was reached by 6.8% of patients allocated to
clopidogrel plus aspirin and by 7.3% of the patients
allocated to placebo plus aspirin (P¼ 0.22). The re-
spective rates of severe bleeding were 1.7% and
1.3% (P¼ 0.09). The risk of moderate bleeding showed
a relative increase of 62% (95% CI [27e110], p< 0.001)
in the clopidogreleaspirin group. The analysis of pre-
defined subgroups suggested that patients defined as
‘‘symptomatic’’ (with major cardiovascular events)
drew more benefit of the dual therapy than ‘‘asymp-
tomatic’’ (with multiple risk factors) patients, with
a marginally significant absolute reduction of 1%
( p¼ 0.046). As stated above, subgroup analyses
should be interpreted with caution, especially as
some of the ‘‘asymptomatic’’ patients had major
cardiovascular events and as ‘‘symptomatic’’ patients
probably had multiple risk factors.40 These results
should be considered as hypothesis generating and
need to be confirmed with trials in specific popula-
tions (i.e. coronary artery disease, cerebral artery
disease, PAD and patients with symptomatic aortic
atheroma.)Eur J Vasc Endovasc Surg Vol 34, July 2007
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setting in the CASPAR study (Clopidogrel and Acetyl-
salicylic acid in bypass Surgery for Peripheral
ARterial disease). This trial is evaluating whether clo-
pidogrel versus placebo (on a background of aspirin
75e100 mg/d) will increase the rate of primary
patency, limb salvage and survival in patients receiv-
ing a below-knee bypass graft for PAD. This study
was recently completed and the results should be
presented in March 2007 at the American College of
Cardiology meeting.
Altogether, available evidence suggests a beneficial
effect of dual APA therapy based on aspirin and clo-
pidogrel in patients with acute coronary artery injury
but not in patients with stable cardiovascular disease.
However, the risk of bleeding is sometimes increased
by this dual APA therapy.
Phosphodiesterase Inhibitors
PDEs are a family of nine enzymes catalyzing the hy-
drolysis of cyclic adenosine monophosphate (cAMP)
and cyclic guanosine monophosphate (cGMP). Dipyr-
idamole and cilostazol act as PDE inhibitors, raising
platelet levels of cyclic adenosine monophosphate
and thereby inhibiting platelet function.41 Dipyrida-
mole also enhances the release and prevents the deg-
radation of endothelial prostaglandin PGI2, a potent
inhibitor of platelet aggregation. These drugs also
have vasodilator activity mediated by an action on
the endothelium.41 Finally, cilostazol inhibits the pro-
liferation of vascular smooth muscle cells.41
Although the clinical benefit of dipyridamole in
the prevention of cardiovascular events in coronary
patients is disappointing,42 with potential adverse
hemodynamic effect,43 PDE inhibitors have recently
been a focus of attention in the treatment of patients
with cerebrovascular disease and those with bare-
metal stents (BMS).44,45
Dual antiplatelet therapy with aspirin and dipyri-
damole was evaluated in cerebrovascular disease
patients in the European Stroke Prevention Study
(ESPS-2), the results of which were recently confirmed
by the ESPRIT trial.44 This latter study, a randomized
open-label trial, evaluated the efficacy of aspirin along
and combined with dipyridamole in 2739 patients
with mildly disabling cerebrovascular disease, over
a mean follow-up of 3.5 years. Meta-analysis of the
two studies showed an absolute reduction of 2.9%
(NNT¼ 35) in the endpoint combining vascular
death, non fatal stroke and myocardial infarction in
the group of patients treated with aspirin and dipyri-
damole compared to patients treated with aspirinEur J Vasc Endovasc Surg Vol 34, July 2007alone. However, 34% of the patients discontinued
the dual therapy because of adverse effects (mainly
headache) compared to 16% of the patients in the
aspirin-alone arm. One limitation of the ESPRIT study
is that 44% of the patients in each arm received only
30 mg of aspirin per day, a dose that is not recommen-
ded for secondary prevention. Some of the results are
surprising: the supplementary benefit of aspirin-
dipyridamole over aspirin alone was larger in the
intention-to-treat analysis than in the on-treatment
analysis and there were significantly fewer major
bleeding events in the combination therapy arm.
The 15500-patient PRoFESS study (the Prevention
Regimen for Effectively Avoiding Second Strokes),
with results expected in 2008, is comparing directly
aspirin plus dipyridamole with clopidogrel mono-
therapy for the prevention of recurrent stroke and
should provide statistically robust estimates of com-
parative efficacy.
Recently cilostazol, having antiproliferative pro-
perties, was evaluated as a systemic therapy for the
prevention of restenosis after BMS implantation, in
the Cilostazol for Restenosis Trial (CREST).45 In this
randomized, double-blind, placebo-controlled trial,
705 patients were allocated to either cilostazol (50 mg
bid) or placebo for 6 months. At 6 months, the intra-
stent late luminal loss was slightly but significantly
lower in the cilostazol-treated group than in the
placebo group (0.91 0.60 vs 1.06 0.69, P¼ 0.01).
There was no difference in the rate of clinical events,
and particularly no excess of bleeding in the cilostazol
group. Owing to its anti-PDE III properties, cilostazol
is contraindicated in patients with severe congestive
heart failure. Indeed, the CREST study excluded
patients with a left ventricular ejection fraction below
30%. The FDA contraindicates cilostazol in patients
with congestive heart failure of any severity (available
on January 14, 2007 at http://www.fda.gov/cder/
news/cilostazol/cilo_label.htm), and this drug is not
currently available in all European countries.
Overall, cilostazol is not recommended for the
prevention of cardiovascular events and its use is cur-
rently limited to the relief of symptoms of claudication
in PAD patients.46
GPIIbIIIa Antagonists
There are currently three classes of GPIIb/IIIa antag-
onist: abciximab, a Fab fragment of a humanized
murine monoclonal antibody; eptifibatide, a synthetic
cyclic heptapeptide; and tirofiban, a non-peptide
antagonist of GPIIb/IIIa. All preparations are admin-
istered intravenously. Oral preparations failed to
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events and were associated with an increase in the
rates of all-cause mortality and bleeding comp-
lications,47 possibly due to incomplete blockade of
GPIIb/IIIa. Intravenous GPIIb/IIIa antagonists are in-
dicated in acute clinical situations and their efficacy is
well documented in the acute coronary syndrome.
The Intracoronary Stenting and Antithrombotic Regi-
men Rapid Early Action for Coronary Treatment 2
trial of abciximab (ISAR-REACT 2) showed a 25%
reduction (relative risk 0.75; 95% CI [0.58e0.97];
P¼ 0.03) in the risk of a composite endpoint (death,
myocardial infarction, or urgent target vessel revascu-
larization) in patients with non-ST-segment elevation
acute coronary syndrome undergoing angioplasty af-
ter pretreatment with 600 mg of clopidogrel.48 Abcix-
imab is also being studied in the treatment of acute
cerebrovascular disease, with promising results.49
Current data do not support the use of GPIIb/IIIa
inhibitors in patients with acute cerebrovascular dis-
ease,50 bleeding risk being a major concern in these
patients but large prospective trials are warranted.
Conclusion
APAs are important agents in themedicalmanagement
of atherothrombosis. Platelets have several amplifica-
tion pathways, and each APA only partially impairs
their function. The combination of aspirin and clopi-
dogrel shows promise in the treatment of patients at
a high risk of vascular occlusion, but it is currently
only recommended in situations of acute coronary
artery injury, such as acute coronary syndrome and
stent implantation, whereas the results of trials in
patients with stable cardiovascular disease favour
monotherapy. The combination of aspirin with dipyri-
damole may be beneficial in cerebrovascular disease
patients, but its use is restricted by adverse side-effects.
New and possibly more potent molecules targeting
thewell-characterizedADP and TA2 platelet amplifi-
cation pathways are under study (Prasugrel51 and
S1888652 for example). There are also many other amp-
lification and regulatory mechanisms53 that are not
directly targeted by current APA and might offer new
drug targets. A closer perspective is the development
of clinically relevant biological tests to determine
APA response. This may soon help tailor APA therapy
and improve the individual risk-benefit ratio.
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